UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2026 (Report No. 2)

 

Commission File Number: 001-38041

 

SCISPARC LTD.

(Translation of registrant’s name into English)

 

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

CONTENTS

 

On July 27, 2026, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity.” On July 29, 2026, the Company issued a press release titled “SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company.” Copies of these press releases are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report of Foreign Private Issuer on Form 6-K (this “Report”) and is incorporated by reference herein.

 

This Report is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408, 333-293167 and 333-293533) and on Form S-8 (File Nos. 333-278437, 333-225773, 333-286791 and 333-292952) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

 

1

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release issued by SciSparc Ltd. titled “SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity.”
99.2   Press release issued by SciSparc Ltd. titled “SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company.”

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SCISPARC LTD.
     
  By: /s/ Oz Adler
  Name:  Oz Adler
  Title: Chief Executive Officer and Chief Financial Officer

 

Date: July 29, 2026

 

3

 

ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC ANNOUNCES DECISION TO TARGET THE AGENTIC AI MARKET; FORMS SCIENTIFIC ADVISORY BOARD FOR ARTIFICIAL INTELLIGENCE AND CYBERSECURITY."

PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC: SUBSIDIARY NEUROTHERA LABS ADVANCES ITS QUANTUM PLATFORM FOR CLINICAL DATA ANALYTICS ON A PLATFORM OF AN S&P 500 COMPANY."